Literature DB >> 27873182

Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials.

Jared R Brosch1, Martin R Farlow2, Shannon L Risacher3, Liana G Apostolova2,3,4.   

Abstract

In vivo imaging of the tau protein has the potential to aid in quantitative diagnosis of Alzheimer's disease, corroborate or dispute the amyloid hypothesis, and demonstrate biomarker engagement in clinical drug trials. A host of tau positron emission tomography agents have been designed, validated, and tested in humans. Several agents have characteristics approaching the ideal imaging tracer with some limitations, primarily regarding off-target binding. Dozens of clinical trials evaluating imaging techniques and several pharmaceutical trials have begun to integrate tau imaging into their protocols.

Entities:  

Keywords:  Alzheimer’s disease; Tau; Tau imaging

Mesh：

Substances：

Year:  2017        PMID： 27873182      PMCID： PMC5233632          DOI： 10.1007/s13311-016-0490-y

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN： 1878-7479            Impact factor:   7.620


  44 in total

1.  Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.

Authors:  Nobuyuki Okamura; Shozo Furumoto; Michelle T Fodero-Tavoletti; Rachel S Mulligan; Ryuichi Harada; Paul Yates; Svetlana Pejoska; Yukitsuka Kudo; Colin L Masters; Kazuhiko Yanai; Christopher C Rowe; Victor L Villemagne
Journal:  Brain       Date:  2014-03-27       Impact factor: 13.501

Review 2.  Alzheimer's disease: the amyloid cascade hypothesis.

Authors:  J A Hardy; G A Higgins
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

3.  Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps.

Authors:  Liana G Apostolova; Rebecca A Dutton; Ivo D Dinov; Kiralee M Hayashi; Arthur W Toga; Jeffrey L Cummings; Paul M Thompson
Journal:  Arch Neurol       Date:  2006-05

4.  Identification of a major radiometabolite of [11C]PBB3.

Authors:  Hiroki Hashimoto; Kazunori Kawamura; Makoto Takei; Nobuyuki Igarashi; Tomoya Fujishiro; Satoshi Shiomi; Ryuji Watanabe; Masatoshi Muto; Kenji Furutsuka; Takehito Ito; Tomoteru Yamasaki; Joji Yui; Kazuyoshi Nemoto; Yasuyuki Kimura; Makoto Higuchi; Ming-Rong Zhang
Journal:  Nucl Med Biol       Date:  2015-09-02       Impact factor: 2.408

Review 5.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

6.  Tau positron emission tomographic imaging in aging and early Alzheimer disease.

Authors:  Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling
Journal:  Ann Neurol       Date:  2015-12-15       Impact factor: 10.422

7.  Longitudinal Assessment of Tau Pathology in Patients with Alzheimer's Disease Using [18F]THK-5117 Positron Emission Tomography.

Authors:  Aiko Ishiki; Nobuyuki Okamura; Katsutoshi Furukawa; Shozo Furumoto; Ryuichi Harada; Naoki Tomita; Kotaro Hiraoka; Shoichi Watanuki; Yoichi Ishikawa; Tetsuro Tago; Yoshihito Funaki; Ren Iwata; Manabu Tashiro; Kazuhiko Yanai; Yukitsuka Kudo; Hiroyuki Arai
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

8.  Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.

Authors:  Stephen D Ginsberg; Shaoli Che; Scott E Counts; Elliott J Mufson
Journal:  J Neurochem       Date:  2006-03       Impact factor: 5.372

Review 9.  Tau imaging in neurodegenerative diseases.

Authors:  M Dani; D J Brooks; P Edison
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-16       Impact factor: 9.236

10.  Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.

Authors:  Konstantinos Chiotis; Laure Saint-Aubert; Irina Savitcheva; Vesna Jelic; Pia Andersen; My Jonasson; Jonas Eriksson; Mark Lubberink; Ove Almkvist; Anders Wall; Gunnar Antoni; Agneta Nordberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-21       Impact factor: 9.236
View more
  9 in total

1.  An Appraisal of Novel Biomarkers for Evaluating and Monitoring Neurologic Diseases: Editorial Introduction.

Authors:  Jeremy M Shefner; Marwan N Sabbagh
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 2.  Alzheimer's Disease: Past, Present, and Future.

Authors:  Mark W Bondi; Emily C Edmonds; David P Salmon
Journal:  J Int Neuropsychol Soc       Date:  2017-10       Impact factor: 2.892

Review 3.  Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology.

Authors:  Harald Hampel; Nicola Toschi; Claudio Babiloni; Filippo Baldacci; Keith L Black; Arun L W Bokde; René S Bun; Francesco Cacciola; Enrica Cavedo; Patrizia A Chiesa; Olivier Colliot; Cristina-Maria Coman; Bruno Dubois; Andrea Duggento; Stanley Durrleman; Maria-Teresa Ferretti; Nathalie George; Remy Genthon; Marie-Odile Habert; Karl Herholz; Yosef Koronyo; Maya Koronyo-Hamaoui; Foudil Lamari; Todd Langevin; Stéphane Lehéricy; Jean Lorenceau; Christian Neri; Robert Nisticò; Francis Nyasse-Messene; Craig Ritchie; Simone Rossi; Emiliano Santarnecchi; Olaf Sporns; Steven R Verdooner; Andrea Vergallo; Nicolas Villain; Erfan Younesi; Francesco Garaci; Simone Lista
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

4.  Vascular endothelial growth factor associated dissimilar cerebrovascular phenotypes in two different mouse models of Alzheimer's Disease.

Authors:  Nicholas M Tataryn; Vishal Singh; Jonathan P Dyke; Hanna E Berk-Rauch; Dana M Clausen; Eric Aronowitz; Erin H Norris; Sidney Strickland; Hyung Jin Ahn
Journal:  Neurobiol Aging       Date:  2021-07-28       Impact factor: 4.673

5.  Evaluation of [18F]-N-Methyl lansoprazole as a Tau PET Imaging Agent in First-in-Human Studies.

Authors:  Vasko Kramer; Allen F Brooks; Arlette Haeger; Rodrigo O Kuljis; Waqas Rafique; Robert A Koeppe; David M Raffel; Kirk A Frey; Horacio Amaral; Peter J H Scott; Patrick J Riss
Journal:  ACS Chem Neurosci       Date:  2020-01-15       Impact factor: 4.418

6.  On the design of early-phase Alzheimer's disease clinical trials with cerebrospinal fluid tau outcomes.

Authors:  Michelle M Nuño; Joshua D Grill; Daniel L Gillen
Journal:  Clin Trials       Date:  2021-07-29       Impact factor: 2.486

Review 7.  A Closer Look into the Role of Protein Tau in the Identification of Promising Therapeutic Targets for Alzheimer's Disease.

Authors:  Rubayat Islam Khan; Saif Shahriar Rahman Nirzhor; Barnaly Rashid
Journal:  Brain Sci       Date:  2018-08-26

8.  Machine learning identified an Alzheimer's disease-related FDG-PET pattern which is also expressed in Lewy body dementia and Parkinson's disease dementia.

Authors:  Audrey Katako; Paul Shelton; Andrew L Goertzen; Daniel Levin; Bohdan Bybel; Maram Aljuaid; Hyun Jin Yoon; Do Young Kang; Seok Min Kim; Chong Sik Lee; Ji Hyun Ko
Journal:  Sci Rep       Date:  2018-09-05       Impact factor: 4.379

9.  The spike-and-slab elastic net as a classification tool in Alzheimer's disease.

Authors:  Justin M Leach; Lloyd J Edwards; Rajesh Kana; Kristina Visscher; Nengjun Yi; Inmaculada Aban
Journal:  PLoS One       Date:  2022-02-03       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.